Xeris Biopharma (NASDAQ:XERS) Sees Unusually-High Trading Volume – Should You Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares saw an uptick in trading volume on Friday . 4,159,031 shares changed hands during mid-day trading, an increase of 93% from the previous session’s volume of 2,159,568 shares.The stock last traded at $4.88 and had previously closed at $4.56.

Wall Street Analyst Weigh In

Several brokerages have commented on XERS. Craig Hallum increased their price target on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Piper Sandler restated a “neutral” rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Leerink Partners upped their price target on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Xeris Biopharma presently has an average rating of “Moderate Buy” and a consensus price target of $5.92.

Xeris Biopharma Stock Performance

The company has a market cap of $741.99 million, a P/E ratio of -10.71 and a beta of 2.32. The stock has a 50-day simple moving average of $3.68 and a 200 day simple moving average of $3.32.

Institutional Investors Weigh In On Xeris Biopharma

A number of institutional investors have recently bought and sold shares of XERS. China Universal Asset Management Co. Ltd. boosted its position in shares of Xeris Biopharma by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after acquiring an additional 2,954 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Xeris Biopharma by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock valued at $273,000 after purchasing an additional 3,447 shares during the period. GPS Wealth Strategies Group LLC raised its holdings in shares of Xeris Biopharma by 6.2% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock worth $227,000 after buying an additional 3,900 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Xeris Biopharma by 31.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after buying an additional 5,500 shares in the last quarter. Finally, Prudential Financial Inc. lifted its position in shares of Xeris Biopharma by 23.4% during the 4th quarter. Prudential Financial Inc. now owns 36,945 shares of the company’s stock worth $125,000 after buying an additional 7,000 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.